Shots: Asterias to receive 0.71 share, for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with two clinical stage candidates i.e. OPC1 & VAC2 The focus of the acquisition is to develop & commercialize novel therapies in fields of Immuno-oncology & […]Read More
Shots: Asterias to receive 0.71 share, for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with two clinical stage candidates i.e. OPC1 & VAC2 The focus of the acquisition is to develop & commercialize novel therapies in fields of Immuno-oncology & […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
